Some patients have mild and often non-specific early symptoms, including shortness of breath after activity, dyspnoea, cyanosis of the lips, pestle and mortar fingers, dry and wet rales or reduced…
Lymphangioleiomyomatosis is now considered to be a low-grade malignant, aggressive, metastatic tumour.
There is currently no cure. Most patients have a continuous decline in lung function and as the disease progresses, dyspnoea becomes more severe and they often die of respiratory failure.…
Patients with lymphangioleiomyomatosis (LAM) are at increased risk of pneumothorax recurrence. There is a lack of studies comparing the prognosis of primary pneumothorax and recurrent pneumothorax in LAM patients undergoing…
Usually lymphangioleiomyomatosis (LAM) progresses gradually and without effective treatment eventually leads to respiratory insufficiency. Lung transplantation remains the only effective treatment for patients with end-stage LAM. Most patients with LAM…
Pulmonary lymphangioleiomyomatosis (LAM) is a rare respiratory disease that occurs only in women, with an average age of onset of 30-40 years. Patients can present with dyspnea, pneumothorax, and celiac…
The FDA approved the Pfizer drug rapamycin (chemical name: sirolimus or rapamycin) that day for the treatment of pulmonary lymphangioleiomyomatosis (LAM), a rare progressive lung disease seen primarily in women…
Guo Xinmei, Department of Internal Tuberculosis, Shandong Chest Hospital Patient, female, 34 years old. History The patient has been experiencing dyspnea with no obvious cause for the past 1 month,…
Seventy percent were reported in the past 6 years A statistical analysis of all medical literature on lymphangioleimyomatosis (LAM) in China from 1981.1.1 to 2009.12.31 showed that the cumulative number…
The lungs have various functions, such as respiratory function, endocrine function, and metabolic function, but the clinical reference to pulmonary function measurement generally refers to the measurement of pulmonary ventilation…